grant
Cannabidiol and Older Adult Cannabis Users: A Randomized, Placebo Controlled Study
Organization UNIVERSITY OF COLORADO DENVERLocation Aurora, UNITED STATESPosted 1 Sept 2023Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY2025(TNF)-α2-AG2-arachidonoyl-glycerol2-arachidonoyl-sn-glycerol2-arachidonoylglycerol2-arachidonyl-glycerol2-arachidonylglycerol65 and older65 or older65 years of age and older65 years of age or more65 years of age or older65+ years65+ years old9-ene-TetrahydrocannabinolAD dementiaAcuteAffectAge associated cognitive deficitAge associated cognitive dysfunctionAge related memory declineAge related memory deficitAge related memory impairmentAge-associated cognitive declineAge-related cognitive declineAged 65 and OverAgingAlzheimer Type DementiaAlzheimer disease dementiaAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's DiseaseAlzheimers DementiaAnalgesia TestsAnimalsAnti-InflammatoriesAnti-Inflammatory AgentsAnti-inflammatoryAnxietyAreaB-Cell Differentiation Factor GeneB-Cell Stimulatory Factor 2 GeneBSF-2 GeneBSF2 GeneBenefits and RisksBenign senescent forgetfulnessBeta-2 Gene InterferonBiologicalBiological MarkersBloodBlood Reticuloendothelial SystemCachectinCannabidiolCannabinoidsCannabisCognitionCognitiveCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalCollectionColoradoCoupledD9-tetrahydrocannabinolDataDelta-9-TetrahydrocannabinolDisturbance in cognitionDizzinessDoseDrowsinessEndocannabinoidsEndogenous CannabinoidsEpidemiological dataEpidemiology dataEquilibriumGoalsHSF GeneHealthHempHepatocyte Stimulatory Factor GeneHybridoma Growth Factor GeneIFNB2 GeneIL-6 GeneIL6IL6 geneImpaired cognitionInflammationInflammatoryInterleukin 6 (Interferon, Beta 2) GeneInterleukin-6 GeneLaboratoriesLinkMacrophage-Derived TNFMediatingMemoryMental DepressionMonocyte-Derived TNFMorbidityMorbidity - disease rateN arachidonoyl 2 hydroxyethylamideN-arachidonoylethanolamineNerve DegenerationNeuron DegenerationNociception TestsOlder PopulationOutcomePainPain AssessmentPain ControlPain MeasurementPain TherapyPain managementPain measurePainfulPlacebo EffectPlacebosPlayPolypharmacyPrevalencePrimary Senile Degenerative DementiaPropertyPublic HealthRandomizedRandomized, Controlled TrialsResearchResearch PriorityRiskRoleSham TreatmentSleepSleep DisordersSomnolenceSurvey InstrumentSurveysTHC co-useTHC useTNFTNF ATNF AlphaTNF geneTNF-αTNFATNFαTetrahydrocannabinolTetrahydrocannabinol co-useTetrahydrocannabinol useTumor Necrosis FactorTumor Necrosis Factor-alphaabove age 65after age 65age 65 and greaterage 65 and olderage 65 or olderageage associated alterationsage associated changesage associated cognitive impairmentage associated memory declineage associated memory deficitage correlated alterationsage correlated changesage dependent alterationsage dependent changesage induced alterationsage induced changesage of 65 years onwardage related alterationsage related changesage related cognitive deficitage related cognitive dysfunctionage related cognitive impairmentage related memory dysfunctionage specific alterationsage specific changesage-associated memory impairmentage-induced cognitive declineage-related decline in cognitionage-related decline in cognitive functionaged 65 and greateraged 65+aged groupaged groupsaged individualaged individualsaged peopleaged personaged personsaged populationaged populationsaged ≥65aging associated alterationsaging associated changesaging correlated alterationsaging correlated changesaging dependent alterationsaging dependent changesaging induced alterationsaging induced changesaging populationaging related alterationsaging related changesaging related cognitive declineaging specific alterationsaging specific changesalterations with ageanandamidearachidonoyl ethanolamidearachidonoylethanolamidearachidonylethanolamidebalancebalance disorderbalance functionbalance impairmentbio-markersbiologicbiologic markerbiomarkercannabis usecannabis userchanges with agechronic pain controlchronic pain interventionchronic pain managementchronic pain therapychronic pain treatmentcognitive dysfunctioncognitive functioncognitive lossdelta(1)-THCdelta(1)-Tetrahydrocannabinoldelta(9)-THCdelta(9)-Tetrahydrocannabinoldepressiondesigndesigningdisturbed balanceeCB systemeconomic costendocannabinoid systemendogenous cannabinoid systemepidemiologic dataequilibration disorderequilibrium disorderexpectancy effectexpectation effectfall riskhuman old age (65+)improvement on sleepinterestmarijuana usemarijuana usermild cognitive disordermild cognitive impairmentmortalitymotor controlnegative affectnegative affectivityneural degenerationneurodegenerationneurodegenerativeneurological degenerationneuronal degenerationneuroprotectionneuroprotectivenoceboolder adultolder adulthoodolder groupsolder individualsolder personover 65 yearspain assaypain interventionpain treatmentplacebo responsepopulation agingprimary degenerative dementiaquality of sleeprandomisationrandomizationrandomized control trialrandomized placebo controlled studyrandomly assignedsenile dementia of the Alzheimer typesham therapyside effectsleep amountsleep diseasessleep durationsleep dysfunctionsleep episodesleep illnesssleep improvementsleep intervalsleep lengthsleep periodsleep problemsleep qualitysleep quantitysleep timesleepinesssocial rolesocio-economicsocio-economicallysocioeconomicallysocioeconomicstime asleeptime during sleeptime in sleeptime spent asleeptime spent sleepingtreat chronic painverbalΔ(1)-THCΔ(1)-tetrahydrocannabinolΔ(9)-THCΔ(9)-tetrahydrocannabinolΔ-9-tetrahydrocannabinolΔ9-tetrahydrocannabinol≥65 years
Description preview
PROJECT SUMMARY/ABSTRACT
PROJECT 3: OLDER ADULT STUDY
Recent epidemiological data indicates a 10-fold increase in cannabis use among older adults (65+
years). Given this rise in use, an important public health question is how cannabis use might impact physical
and cognitive health in older individuals, especially since they are at increased risk…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click